Matthew Wood

Matthew Wood


Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 December 2006 in Nature
Verified
Journal Article
Closed access
PDF file
ELEd S. Lein
Ed S. Lein
MHMichael J. Hawrylycz
Michael J. Hawrylycz
NANancy Ao
Nancy Ao
MAMikael Ayres
Mikael Ayres
ABAmy Bensinger
Amy Bensinger
AJAllan R. Jones
Allan R. Jones

20 March 2011 in Nature Biotechnology
Verified
Journal Article
Closed access
PDF file
ALAlvarez-Erviti Lydia
Alvarez-Erviti Lydia
YSYiqi Seow
Yiqi Seow
HYHaiFang Yin
HaiFang Yin
CBCorinne Betts
Corinne Betts
SLSamira Lakhal
Samira Lakhal
MWMatthew Wood
Matthew Wood

15 April 2013 in Nature Reviews Drug Discovery
Verified
Journal Article
Closed access
PDF file
SASamir EL Andaloussi
Samir EL Andaloussi
IMImre Mäger
Imre Mäger
XBXandra O. Breakefield
Xandra O. Breakefield
MWMatthew Wood
Matthew Wood

11 August 2020 in Nature Reviews Drug Discovery
Verified
Journal Article
Closed access
PDF file
TRThomas Roberts
Thomas Roberts
RLRobert Langer
Robert Langer
MWMatthew Wood
Matthew Wood

1 July 2021 in Nature Nanotechnology
Verified
Journal Article
Closed access
PDF file
Inge HerrmannInge Herrmann
Inge Herrmann
MWMatthew Wood
Matthew Wood
GFGregor Fuhrmann
Gregor Fuhrmann

1 January 2015 in Journal of Extracellular Vesicles
Verified
Journal Article
Open access
OWOscar P. B. Wiklander
Oscar P. B. Wiklander
JNJoel Nordin
Joel Nordin
AOAisling O'LOughlin
Aisling O'LOughlin
YGYlva Gustafsson
Ylva Gustafsson
GCGiulia Corso
Giulia Corso
OGOskar Gustafsson
Oskar Gustafsson
Extracellular vesicles (EVs) have emerged as important mediators of intercellular communication in a diverse range of biological processes. For future therapeutic applications and for EV biology research in general, understanding the in vivo fate of EVs is of utmost importance. Here we studied biodistribution of EVs in mice after systemic delivery. EVs were isolated from 3 different mouse cell sources, including dendritic cells (DCs) derived from bone marrow, and labelled with a near‐infrared lipophilic dye. Xenotransplantation of EVs was further carried out for cross‐species comparison. The reliability of the labelling technique was confirmed by sucrose gradient fractionation, organ perfusion and further supported by immunohistochemical staining using CD63‐EGFP probed vesicles. While vesicles accumulated mainly in liver, spleen, gastrointestinal tract and lungs, differences related to EV cell origin were detected. EVs accumulated in the tumour tissue of tumour‐bearing mice and, after introduction of the rabies virus glycoprotein‐targeting moiety, they were found more readily in acetylcholine‐receptor‐rich organs. In addition, the route of administration and the dose of injected EVs influenced the biodistribution pattern. This is the first extensive biodistribution investigation of EVs comparing the impact of several different variables, the results of which have implications for the design and feasibility of therapeutic studies using EVs.